Table 5.
Number and rates (per 1000 screening examinations) of screen-detected cancer, false-positive screening examinations (n, per 100 screening examinations) and positive predictive value of recalls (PPV-1) and invasive procedures (PPV-2) by time since last screening examination
| US | Norway | Spain | |||||
|---|---|---|---|---|---|---|---|
| <18 months | 18-30 months | >30 months | 18-30 months | >30 months | 18-30 months | >30 months | |
| (n = 1,635,247) | (n = 496,738) | (n = 255,126) | (n = 903,709) | (n = 39,681) | (n = 1,003,210) | (n = 65,379) | |
| Screen-detected cancers (n, rate per 1000 screening examinations) | |||||||
| All malignancies | 5927 (3.6 ‰) | 2363 (4.8 ‰) | 1692 (6.6 ‰) | 4486 (5.0 ‰) | 311 (7.8 ‰) | 3501 (3.5 ‰) | 350 (5.4 ‰) |
| Invasive | 4383 (2.7 ‰) | 1814 (3.7 ‰) | 1332 (5.2 ‰) | 3723 (4.1 ‰) | 265 (6.7 ‰) | 2798 (2.8 ‰) | 274 (4.2 ‰) |
| DCIS | 1544 (0.9 ‰) | 549 (1.1 ‰) | 360 (1.4 ‰) | 763 (0.8 ‰) | 46 (1.2 ‰) | 550 (0.5 ‰) | 59 (0.9 ‰) |
| Unknown | 0 | 0 | 0 | 0 | 0 | 153 (0.2 ‰) | 17 (0.3 ‰) |
| False positives (n, rate per 100 screening examinations) | |||||||
| Additional images | 124,896 (7.6 %) | 42,644 (8.6 %) | 26,784 (10.5 %) | 19,068 (2.1 %) | 1,181 (3.0 %) | 26,731 (2.7 %) | 2345 (3.6 %) |
| Invasive procedures | 12,702 (0.8 %) | 4220 (0.8 %) | 3268 (1.3 %) | 4805 (0.5 %) | 387 (1.0 %) | 3615 (0.4 %) | 316 (0.5 %) |
| Positive predictive value (%, 95 % CI) | |||||||
| PPV-1 | 4.5 (4.4-4-6) | 5.2 (5.0 - 5.4) | 5.9 (5.6 - 6.2) | 19.4 (18.9-19.9) | 21.4 (19.4-23.6) | 11.6 (11.6-11.6) | 13.0 (13.0-13.0) |
| PPV-2 | 25.2 (24.5-25.8) | 29.5 (28.4-30.7) | 27.7 (26.5-29.0) | 48.3 (47.3-49.3) | 44.6 (47.3-49.3) | 49.7 (49.7-49.7) | 52.6 (52.5-52.5) |